Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239,546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.
Karvouni M, Vidal-Manrique M, Susek KH, Hussain A, Gilljam M, Zhang Y, Gray JD, Lund J, Kaufmann G, Ljunggren HG, Ji H, Lundqvist A, Wagner AK, Guo W, Alici E. Karvouni M, et al. Among authors: zhang y. Cytotherapy. 2023 Jul;25(7):763-772. doi: 10.1016/j.jcyt.2023.03.006. Epub 2023 Apr 11. Cytotherapy. 2023. PMID: 37055320 Free article.
Discovery of novel cMET-targeting antibody Fab drug conjugates as potential treatment for solid tumors with highly expressed cMET.
Lim RK, Buschman M, Khasanov A, Ledesma A, Chen J, Nguyen T, Guo J, Li L, Huang J, Niu J, Kerwin L, Wang R, Guo Y, Zhu T, Kaufmann G, Zhang Y, Zhou H, Ji H, Fu Y. Lim RK, et al. Among authors: zhang y. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1137-1149. doi: 10.1080/14712598.2023.2292633. Epub 2023 Dec 15. Expert Opin Biol Ther. 2023. PMID: 38078403
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Duty JA, Kraus T, Zhou H, Zhang Y, Shaabani N, Yildiz S, Du N, Singh A, Miorin L, Li D, Stegman K, Ophir S, Cao X, Atanasoff K, Lim R, Mena I, Bouvier NM, Kowdle S, Carreño JM, Rivero-Nava L, Raskin A, Moreno E, Johnson S, Rathnasinghe R, Pai CI, Kehrer T, Cabral EP, Jangra S, Healy L, Singh G, Warang P, Simon V, Sordillo EM, van Bakel H, Liu Y, Sun W, Kerwin L, Teijaro J, Schotsaert M, Krammer F, Bresson D, García-Sastre A, Fu Y, Lee B, Powers C, Moran T, Ji H, Tortorella D, Allen R. Duty JA, et al. Among authors: zhang y. Med. 2022 Oct 14;3(10):705-721.e11. doi: 10.1016/j.medj.2022.08.002. Epub 2022 Aug 8. Med. 2022. PMID: 36044897 Free PMC article.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Cao X, Maruyama J, Zhou H, Fu Y, Kerwin L, Powers C, Sattler RA, Manning JT, Singh A, Lim R, Healy LD, Johnson S, Paz Cabral E, Li D, Lu L, Ledesma A, Lee D, Richards S, Rivero-Nava L, Li Y, Shen W, Stegman K, Blair B, Urata S, Kishimoto-Urata M, Ko J, Du N, Morais K, Lawrence K, Rivera I, Pai CI, Bresson D, Brunswick M, Zhang Y, Ji H, Paessler S, Allen RD. Cao X, et al. Among authors: zhang y. Sci Rep. 2022 Sep 15;12(1):15517. doi: 10.1038/s41598-022-19780-7. Sci Rep. 2022. PMID: 36109550 Free PMC article.
SARS-CoV-2 monoclonal antibodies with therapeutic potential: Broad neutralizing activity and No evidence of antibody-dependent enhancement.
Wang YT, Allen RD 3rd, Kim K, Shafee N, Gonzalez AJ, Nguyen MN, Valentine KM, Cao X, Lu L, Pai CI, Johnson S, Kerwin L, Zhou H, Zhang Y, Shresta S. Wang YT, et al. Among authors: zhang y. Antiviral Res. 2021 Nov;195:105185. doi: 10.1016/j.antiviral.2021.105185. Epub 2021 Oct 8. Antiviral Res. 2021. PMID: 34634289 Free PMC article.
239,546 results
You have reached the last available page of results. Please see the User Guide for more information.